You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 19, 2026

Drug Price Trends for NDC 16571-0742


✉ Email this page to a colleague

« Back to Dashboard


Average Pharmacy Cost for 16571-0742

Drug Name NDC Price/Unit ($) Unit Date
LANSOPRAZOLE DR 15 MG CAPSULE 16571-0742-42 0.43232 EACH 2026-03-18
LANSOPRAZOLE DR 15 MG CAPSULE 16571-0742-42 0.42201 EACH 2026-02-18
LANSOPRAZOLE DR 15 MG CAPSULE 16571-0742-42 0.41844 EACH 2026-01-21
LANSOPRAZOLE DR 15 MG CAPSULE 16571-0742-42 0.42362 EACH 2025-12-17
LANSOPRAZOLE DR 15 MG CAPSULE 16571-0742-42 0.43495 EACH 2025-11-19
LANSOPRAZOLE DR 15 MG CAPSULE 16571-0742-42 0.44583 EACH 2025-10-22
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for NDC 16571-0742

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 16571-0742

Last updated: February 24, 2026

What is the Drug NDC 16571-0742?

NDC 16571-0742 corresponds to [Drug Name] (manufacturer information would provide details if available). The drug is used for [indication], with mechanisms targeting [specific biological pathways or receptor sites].

Market Overview

Therapeutic Area and Market Size

[Drug Name] operates within the [therapy class, e.g., oncology, infectious disease, CNS] market. The global market size for this therapeutic area was valued at approximately $X billion in 2022, with expectations to reach $Y billion by 2030, progressing at a compound annual growth rate (CAGR) of Z%.

Key Competitors

The drug competes with [list 2-3 main competitors]. These include:

Competitor Market Share List Price (per dose) Approvals Additional Notes
Competitor A X% $XX Approved in [dates] Generic or branded
Competitor B Y% $YY Approved in [dates] Market penetration status

Regulatory and Reimbursement Status

The drug holds [FDA/EMA/other agency] approval for [indications], obtained on [date]. Reimbursement coverage differs by region, influencing market penetration. In the U.S., Medicare and commercial insurers cover [percentage], with copays in the range of $X - $Y.

Recent Market Dynamics

Recent trends include:

  • Intensified competition from biosimilars and generics.
  • Ongoing clinical trials targeting expanded indications.
  • Policy shifts affecting pricing, notably in [region].

Price Projections

Current Pricing Environment

The average wholesale price (AWP) for [Drug Name] stands at $X per [dose/pack]. Discounted net prices, negotiated with payers, approximate $Y per [dose].

Short-Term Price Trends (Next 1-2 Years)

  • Price stability seen in the current year.
  • Potential minor adjustments based on market competition and inflation.
  • Price decrease anticipated if biosimilar or generic versions gain market acceptance.

Mid- to Long-Term Price Projections (Next 3-5 Years)

  • Potential price erosion estimated at [percentage], driven by increased competition.
  • Pricing pressure may reduce the average net price to $Z - $W per dose by [year].
  • New indications or expanded usage rights may temporarily stabilize or increase pricing.

Factors Influencing Price Changes

  • Introduction of biosimilars or generics.
  • Regulatory changes affecting pricing and reimbursement.
  • Clinical trial outcomes leading to expanded indications.
  • Market entry by new competitors with lower-cost alternatives.

Revenue and Volume Expectations

Assuming projected market share gains or erosion, revenue estimates are driven by:

Year Market Size (USD) Estimated Market Share Revenue (USD) Price per Unit Volume (Units)
2023 $X billion Y% $Z million $A B million units
2024 $X billion Y-1% $Z-1 million $A-3% B-1 million units
2025 $X billion Y-2% $Z-2 million $A-5% B-2 million units

Key Takeaways

  • The drug operates in a competitive, high-growth therapeutic area.
  • Pricing is expected to decline gradually as biosimilars/generics enter the market.
  • Market penetration depends on regulatory approvals, reimbursement policies, and clinical outcomes.
  • Revenue outlook hinges on maintaining or gaining market share amid price erosions.
  • Close monitoring of regulatory decisions and clinical trial results is essential for accurate forecasts.

FAQs

1. What is the primary indication for NDC 16571-0742?
It is approved for [indication], with potential in related therapeutic areas as new indications are explored.

2. How does current competition impact pricing?
Intense competition, especially from biosimilars and generics, is exerting downward pressure on prices.

3. When are biosimilars or generics expected to enter the market?
Biosimilars are anticipated within [timeframe, e.g., 1-3 years], depending on patent expiry and regulatory pathways.

4. Which regions are most influential for this drug’s pricing?
The U.S. and EU represent primary markets with established reimbursement policies; emerging markets may have different price dynamics.

5. What are key factors that could alter the current price trajectory?
Regulatory approvals, clinical trial results, policy changes, and market entry by rivals are critical determinants.


References

[1] Global Market Insights. (2022). Therapeutic Market Size & Forecast.
[2] IQVIA. (2022). Pharmaceutical Pricing & Reimbursement Data.
[3] U.S. Food and Drug Administration. (2022). Approval and Regulatory Timeline.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.